We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

SeraCare, TOMA Biosciences Announce Partnership

SeraCare, TOMA Biosciences Announce Partnership

SeraCare, TOMA Biosciences Announce Partnership

SeraCare, TOMA Biosciences Announce Partnership

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SeraCare, TOMA Biosciences Announce Partnership"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SeraCare Life Sciences and TOMA Biosciences have announced a co-development partnership during the 2016 American Association of Cancer Research in New Orleans. Under the terms of the agreement, SeraCare will provide TOMA Biosciences access to their Seraseq™ Solid Tumor Mutation Mix reference material technology to support the development and validation of the TOMA OS-Seq™ comprehensive solid tumor gene analysis kit, as well as their upcoming PlasmaSeq™ liquid biopsy test.

TOMA Bioscience’s OS-Seq proprietary technology permits researchers to evaluate in toto each gene in its panel for all mutation types, including Copy Number Alterations (CNAs), with a simplified single day library prep method. The accurate detection of CNAs, single-nucleotide variants, insertion-deletion mutations, and DNA translocations requires well-characterized reference standard material to assist with both assay development and routine assay quality assurance.

The Seraseq Solid Tumor Mutation Mix technology offers the broadest selection of actionable and hard-to-sequence somatic variants at precise allelic frequencies within a well characterized reference genome background.

“Seraseq reference materials offer a comprehensive and customizable set of mutations which are ideally suited to the comprehensive nature of the TOMA OS-Seq reagent kit,” said Federico Goodsaid, Ph.D., Vice President of Assay Development and Regulatory Affairs at TOMA Biosciences. “More importantly, we share the vision of a strong quality and regulatory approach when bringing validated NGS-based tumor profiling assays to market.”

“We are very excited to be working with TOMA Biosciences and supporting their innovative OS-Seq technology with our Seraseq technology,” said Trevor Brown, Vice President of Precision Medicine at SeraCare. “SeraCare has 30 years of experience providing high value tools for assay developers and clinical laboratories and strong experience with the 510k/IVD regulatory path.”

Our goal is to seek out mutually beneficial partnerships with NGS-based assay developers that leverage our ever growing pipeline of innovative tools supporting better data quality in precision diagnostics.”